Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zinforo

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

New data backs Pfizer’s Eliquis in atrial fibrillation

Findings bode well for the drug's commercial prospects

- PMLiVE

India revokes Pfizer’s patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

Shionogi-ViiV to file HIV drug dolutegravir for approval

GSK, Pfizer and Shionogi joint venture completes phase III trials programme

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Pfizer calls on pharmacists to promote medicine adherence

Unused medicines cost NHS England £300m per year

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links